Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has...
Day: May 23, 2022
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
– Six abstracts presented highlighting data on BylvayTM(odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters –...
WIMI Hologram Academy: Psychological application of multi-perceptual interactive experience of virtual reality technology
HONG KONG, May 23, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates...
Innoviva to Acquire Entasis Therapeutics
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per...
Nanomix Announces Upgrade to OTCQB® Venture Market
EMERYVILLE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the...
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
Quoin obtains option to exclusive global rights to product; no upfront or milestone feesASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE)...
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
The partnership will evaluate Lupagen’s extracorporeal in vivo delivery technology as a potential additional route of administration for Umoja’s VivoVec...
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Milestone Scientific Announces the Appointment of Retail Industry Veteran Ms. Benedetta Casamento to its Board of Directors
ROSELAND, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
IO Biotech to Participate in the Jefferies Healthcare Conference
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT
Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT CEO Mike O’Shea of...
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater...
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A....
Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee...
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of...
Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD
Independent safety review approved dose escalation and initiation of third and final dosing cohortSTAR-LLD well tolerated in all subjects dosed...